Cerebrospinal fluid lactoperoxidase level is enhanced in idiopathic Parkinson’s disease, and correlates with levodopa equivalent daily dose
•Lactoperoxidase concentration is enhanced in the cerebrospinal fluid in parkinsonian patients.•Lactoperoxidase in the cerebrospinal fluid holds promise as biomarker of Parkinsońs disease.•High levodopa equivalent daily doses attenuate elevated lactoperoxidase concentration in the cerebrospinal flui...
Gespeichert in:
| Veröffentlicht in: | Brain research 2021-06, Vol.1761, p.147411-147411, Article 147411 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 147411 |
|---|---|
| container_issue | |
| container_start_page | 147411 |
| container_title | Brain research |
| container_volume | 1761 |
| creator | Fernández-Espejo, Emilio Rodriguez de Fonseca, Fernando Suárez, Juan Martín de Pablos, Ángel |
| description | •Lactoperoxidase concentration is enhanced in the cerebrospinal fluid in parkinsonian patients.•Lactoperoxidase in the cerebrospinal fluid holds promise as biomarker of Parkinsońs disease.•High levodopa equivalent daily doses attenuate elevated lactoperoxidase concentration in the cerebrospinal fluid.•High levodopa equivalent daily doses induce motor complications in patients.
Lactoperoxidase (LPO) is proposed to play a role in the pathogenesis of Parkinson’s disease (PD). This enzyme has been reported to be enhanced in the cerebrospinal fluid (CSF) in parkinsonian patients. The objective was to look at the relationship of LPO in the CSF and serum with clinical features of idiopathic PD. LPO concentration was analyzed through ELISA techniques. Correlation of CSF or serum LPO and MDS-UPDRS, dopaminergic medication, and other clinical parameters was examined. The findings revealed that LPO concentration in the CSF, not serum, was found to be elevated in patients with PD relative to controls (p |
| doi_str_mv | 10.1016/j.brainres.2021.147411 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2498997937</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006899321001360</els_id><sourcerecordid>2498997937</sourcerecordid><originalsourceid>FETCH-LOGICAL-c368t-4d6216503ba6c198dd5d7e729d9e5b0466bc28e89bbe8794236d24ce2a73c4be3</originalsourceid><addsrcrecordid>eNqFkU1uFDEQhS1ERIaEK0ResqAH__S42zvQiD8pEiySteW2azQ1eOyO3T0hOy7AAbgeJ8GjSdiyKpX0vleq9wi54mzJGVdvd8shW4wZylIwwZe87VrOn5EF7zvRKNGy52TBGFNNr7U8Jy9L2dVVSs1ekHMpVae01Avyaw0ZhpzKiNEGugkzehqsm9IIOf1AbwvQAAcIFAuFuLXRgacYKXpMo5226Og3m79jLCn--fm7UI8FKvWG2uipSzlDsBMUeo_T9miVfOUo3M14sAHiRL3F8EB9KnBJzjY2FHj1OC_I7ccPN-vPzfXXT1_W768bJ1U_Na1XgqsVk4NVjuve-5XvoBPaa1gNrFVqcKKHXg8D9J1uhVRetA6E7aRrB5AX5PXJd8zpboYymT0WByHYCGkuRrS6xtZp2VWpOkldDalk2Jgx497mB8OZOVZhduapCnOswpyqqODV44152IP_hz1lXwXvTgKonx4QsikO4RgvZnCT8Qn_d-Mv2tSiXg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2498997937</pqid></control><display><type>article</type><title>Cerebrospinal fluid lactoperoxidase level is enhanced in idiopathic Parkinson’s disease, and correlates with levodopa equivalent daily dose</title><source>Elsevier ScienceDirect Journals</source><creator>Fernández-Espejo, Emilio ; Rodriguez de Fonseca, Fernando ; Suárez, Juan ; Martín de Pablos, Ángel</creator><creatorcontrib>Fernández-Espejo, Emilio ; Rodriguez de Fonseca, Fernando ; Suárez, Juan ; Martín de Pablos, Ángel</creatorcontrib><description>•Lactoperoxidase concentration is enhanced in the cerebrospinal fluid in parkinsonian patients.•Lactoperoxidase in the cerebrospinal fluid holds promise as biomarker of Parkinsońs disease.•High levodopa equivalent daily doses attenuate elevated lactoperoxidase concentration in the cerebrospinal fluid.•High levodopa equivalent daily doses induce motor complications in patients.
Lactoperoxidase (LPO) is proposed to play a role in the pathogenesis of Parkinson’s disease (PD). This enzyme has been reported to be enhanced in the cerebrospinal fluid (CSF) in parkinsonian patients. The objective was to look at the relationship of LPO in the CSF and serum with clinical features of idiopathic PD. LPO concentration was analyzed through ELISA techniques. Correlation of CSF or serum LPO and MDS-UPDRS, dopaminergic medication, and other clinical parameters was examined. The findings revealed that LPO concentration in the CSF, not serum, was found to be elevated in patients with PD relative to controls (p < 0.001). CSF LPO concentration negatively correlated with MDS-UPDRS part-IV score (p < .0001), a rating scale that allows evaluating motor complications. CSF LPO level inversely correlated with the dose intensity of the dopaminergic medication regimen, as evaluated with levodopa equivalent dose or LED (mg/day; p < .0001). LED value positively correlated with MDS-UPDRS part-IV score (p < .0001). To sum up, the findings indicate that CSF LPO is found to be elevated in the CSF of PD patients, and this enzyme holds promise as potential biomarker for diagnosis of PD. Increasing the dose intensity of the dopaminergic medication regimen attenuates the elevation in LPO levels in the CSF, and it facilitates the development of motor complications in patients. The pathophysiological mechanisms that seem to be responsible for LPO increase would include dopamine deficiency, oxidative stress, and less likely, microbial infection.</description><identifier>ISSN: 0006-8993</identifier><identifier>EISSN: 1872-6240</identifier><identifier>DOI: 10.1016/j.brainres.2021.147411</identifier><identifier>PMID: 33676939</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Cerebrospinal fluid ; Lactoperoxidase ; Levodopa equivalent dose ; Parkinson’s disease ; Serum</subject><ispartof>Brain research, 2021-06, Vol.1761, p.147411-147411, Article 147411</ispartof><rights>2021 Elsevier B.V.</rights><rights>Copyright © 2021 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c368t-4d6216503ba6c198dd5d7e729d9e5b0466bc28e89bbe8794236d24ce2a73c4be3</citedby><cites>FETCH-LOGICAL-c368t-4d6216503ba6c198dd5d7e729d9e5b0466bc28e89bbe8794236d24ce2a73c4be3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0006899321001360$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33676939$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fernández-Espejo, Emilio</creatorcontrib><creatorcontrib>Rodriguez de Fonseca, Fernando</creatorcontrib><creatorcontrib>Suárez, Juan</creatorcontrib><creatorcontrib>Martín de Pablos, Ángel</creatorcontrib><title>Cerebrospinal fluid lactoperoxidase level is enhanced in idiopathic Parkinson’s disease, and correlates with levodopa equivalent daily dose</title><title>Brain research</title><addtitle>Brain Res</addtitle><description>•Lactoperoxidase concentration is enhanced in the cerebrospinal fluid in parkinsonian patients.•Lactoperoxidase in the cerebrospinal fluid holds promise as biomarker of Parkinsońs disease.•High levodopa equivalent daily doses attenuate elevated lactoperoxidase concentration in the cerebrospinal fluid.•High levodopa equivalent daily doses induce motor complications in patients.
Lactoperoxidase (LPO) is proposed to play a role in the pathogenesis of Parkinson’s disease (PD). This enzyme has been reported to be enhanced in the cerebrospinal fluid (CSF) in parkinsonian patients. The objective was to look at the relationship of LPO in the CSF and serum with clinical features of idiopathic PD. LPO concentration was analyzed through ELISA techniques. Correlation of CSF or serum LPO and MDS-UPDRS, dopaminergic medication, and other clinical parameters was examined. The findings revealed that LPO concentration in the CSF, not serum, was found to be elevated in patients with PD relative to controls (p < 0.001). CSF LPO concentration negatively correlated with MDS-UPDRS part-IV score (p < .0001), a rating scale that allows evaluating motor complications. CSF LPO level inversely correlated with the dose intensity of the dopaminergic medication regimen, as evaluated with levodopa equivalent dose or LED (mg/day; p < .0001). LED value positively correlated with MDS-UPDRS part-IV score (p < .0001). To sum up, the findings indicate that CSF LPO is found to be elevated in the CSF of PD patients, and this enzyme holds promise as potential biomarker for diagnosis of PD. Increasing the dose intensity of the dopaminergic medication regimen attenuates the elevation in LPO levels in the CSF, and it facilitates the development of motor complications in patients. The pathophysiological mechanisms that seem to be responsible for LPO increase would include dopamine deficiency, oxidative stress, and less likely, microbial infection.</description><subject>Cerebrospinal fluid</subject><subject>Lactoperoxidase</subject><subject>Levodopa equivalent dose</subject><subject>Parkinson’s disease</subject><subject>Serum</subject><issn>0006-8993</issn><issn>1872-6240</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNqFkU1uFDEQhS1ERIaEK0ResqAH__S42zvQiD8pEiySteW2azQ1eOyO3T0hOy7AAbgeJ8GjSdiyKpX0vleq9wi54mzJGVdvd8shW4wZylIwwZe87VrOn5EF7zvRKNGy52TBGFNNr7U8Jy9L2dVVSs1ekHMpVae01Avyaw0ZhpzKiNEGugkzehqsm9IIOf1AbwvQAAcIFAuFuLXRgacYKXpMo5226Og3m79jLCn--fm7UI8FKvWG2uipSzlDsBMUeo_T9miVfOUo3M14sAHiRL3F8EB9KnBJzjY2FHj1OC_I7ccPN-vPzfXXT1_W768bJ1U_Na1XgqsVk4NVjuve-5XvoBPaa1gNrFVqcKKHXg8D9J1uhVRetA6E7aRrB5AX5PXJd8zpboYymT0WByHYCGkuRrS6xtZp2VWpOkldDalk2Jgx497mB8OZOVZhduapCnOswpyqqODV44152IP_hz1lXwXvTgKonx4QsikO4RgvZnCT8Qn_d-Mv2tSiXg</recordid><startdate>20210615</startdate><enddate>20210615</enddate><creator>Fernández-Espejo, Emilio</creator><creator>Rodriguez de Fonseca, Fernando</creator><creator>Suárez, Juan</creator><creator>Martín de Pablos, Ángel</creator><general>Elsevier B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20210615</creationdate><title>Cerebrospinal fluid lactoperoxidase level is enhanced in idiopathic Parkinson’s disease, and correlates with levodopa equivalent daily dose</title><author>Fernández-Espejo, Emilio ; Rodriguez de Fonseca, Fernando ; Suárez, Juan ; Martín de Pablos, Ángel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c368t-4d6216503ba6c198dd5d7e729d9e5b0466bc28e89bbe8794236d24ce2a73c4be3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Cerebrospinal fluid</topic><topic>Lactoperoxidase</topic><topic>Levodopa equivalent dose</topic><topic>Parkinson’s disease</topic><topic>Serum</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fernández-Espejo, Emilio</creatorcontrib><creatorcontrib>Rodriguez de Fonseca, Fernando</creatorcontrib><creatorcontrib>Suárez, Juan</creatorcontrib><creatorcontrib>Martín de Pablos, Ángel</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Brain research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fernández-Espejo, Emilio</au><au>Rodriguez de Fonseca, Fernando</au><au>Suárez, Juan</au><au>Martín de Pablos, Ángel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cerebrospinal fluid lactoperoxidase level is enhanced in idiopathic Parkinson’s disease, and correlates with levodopa equivalent daily dose</atitle><jtitle>Brain research</jtitle><addtitle>Brain Res</addtitle><date>2021-06-15</date><risdate>2021</risdate><volume>1761</volume><spage>147411</spage><epage>147411</epage><pages>147411-147411</pages><artnum>147411</artnum><issn>0006-8993</issn><eissn>1872-6240</eissn><abstract>•Lactoperoxidase concentration is enhanced in the cerebrospinal fluid in parkinsonian patients.•Lactoperoxidase in the cerebrospinal fluid holds promise as biomarker of Parkinsońs disease.•High levodopa equivalent daily doses attenuate elevated lactoperoxidase concentration in the cerebrospinal fluid.•High levodopa equivalent daily doses induce motor complications in patients.
Lactoperoxidase (LPO) is proposed to play a role in the pathogenesis of Parkinson’s disease (PD). This enzyme has been reported to be enhanced in the cerebrospinal fluid (CSF) in parkinsonian patients. The objective was to look at the relationship of LPO in the CSF and serum with clinical features of idiopathic PD. LPO concentration was analyzed through ELISA techniques. Correlation of CSF or serum LPO and MDS-UPDRS, dopaminergic medication, and other clinical parameters was examined. The findings revealed that LPO concentration in the CSF, not serum, was found to be elevated in patients with PD relative to controls (p < 0.001). CSF LPO concentration negatively correlated with MDS-UPDRS part-IV score (p < .0001), a rating scale that allows evaluating motor complications. CSF LPO level inversely correlated with the dose intensity of the dopaminergic medication regimen, as evaluated with levodopa equivalent dose or LED (mg/day; p < .0001). LED value positively correlated with MDS-UPDRS part-IV score (p < .0001). To sum up, the findings indicate that CSF LPO is found to be elevated in the CSF of PD patients, and this enzyme holds promise as potential biomarker for diagnosis of PD. Increasing the dose intensity of the dopaminergic medication regimen attenuates the elevation in LPO levels in the CSF, and it facilitates the development of motor complications in patients. The pathophysiological mechanisms that seem to be responsible for LPO increase would include dopamine deficiency, oxidative stress, and less likely, microbial infection.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>33676939</pmid><doi>10.1016/j.brainres.2021.147411</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-8993 |
| ispartof | Brain research, 2021-06, Vol.1761, p.147411-147411, Article 147411 |
| issn | 0006-8993 1872-6240 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2498997937 |
| source | Elsevier ScienceDirect Journals |
| subjects | Cerebrospinal fluid Lactoperoxidase Levodopa equivalent dose Parkinson’s disease Serum |
| title | Cerebrospinal fluid lactoperoxidase level is enhanced in idiopathic Parkinson’s disease, and correlates with levodopa equivalent daily dose |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T02%3A06%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cerebrospinal%20fluid%20lactoperoxidase%20level%20is%20enhanced%20in%20idiopathic%20Parkinson%E2%80%99s%20disease,%20and%20correlates%20with%20levodopa%20equivalent%20daily%20dose&rft.jtitle=Brain%20research&rft.au=Fern%C3%A1ndez-Espejo,%20Emilio&rft.date=2021-06-15&rft.volume=1761&rft.spage=147411&rft.epage=147411&rft.pages=147411-147411&rft.artnum=147411&rft.issn=0006-8993&rft.eissn=1872-6240&rft_id=info:doi/10.1016/j.brainres.2021.147411&rft_dat=%3Cproquest_cross%3E2498997937%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2498997937&rft_id=info:pmid/33676939&rft_els_id=S0006899321001360&rfr_iscdi=true |